This facility is expected to significantly improve the lives of patient populations by facilitating development of innovative therapies. For example, BlueRock Therapeutics is currently differentiating stem cells into neurons, retinal photoreceptors, and cardiomyocytes. Dopamine-producing neurons could be implanted into the brain to stop or reverse Parkinsons disease, which affects over 10 million people worldwide. The facility aims to provide hope and strive for a cure for patients with unmet medical needs by making these life-changing therapies more accessible to all.
For these reasons, Bayer’s Cell Therapy Launch and Manufacturing Facility is recognized as the 2025 ISPE FOYA Category Winner for Social Impact, Unmet Medical Needs.
The call for submissions is now open for the 2026 ISPE FOYA program, ending Friday, 5 December. The 2026 ISPE FOYA submission finalists will be announced at the 2026 ISPE Facilities of the Future Conference, taking place 2–3 February 2026 in San Diego, California, USA.
Established in 2005, the FOYA program recognizes state-of-the-art projects utilizing new, innovative technologies to improve the quality of products, reduce the cost of producing high-quality medicines, and demonstrate advances in project delivery. The FOYA program provides a platform for the pharmaceutical science and manufacturing industry to showcase its accomplishments in facility design, construction, and operation, while sharing the development of new applications of technology and cutting-edge approaches.
